A truncated IGF-1 variant lacking the first 3 amino acids — extremely potent with minimal binding protein interaction.
IGF-1 DES (des(1-3) IGF-1) is a truncated variant of insulin-like growth factor 1 that lacks the first three N-terminal amino acids (Gly-Pro-Glu). This truncation renders it essentially invisible to IGF binding proteins (IGFBPs), giving it approximately 10x greater potency than native IGF-1 but with a very short half-life (~20-30 minutes).
The extreme potency and short half-life make IGF-1 DES particularly suited for localized effects — when injected near a specific muscle or tissue, it acts rapidly and potently before being cleared. This pharmacokinetic profile is distinct from IGF-1 LR3, which has systemic, long-lasting effects.
IGF-1 DES is a research compound with extremely limited clinical data and significant risks similar to IGF-1 LR3. Its use outside of research is not recommended.
Research shows IGF-1 DES has approximately 10-fold greater mitogenic (growth-promoting) potency than native IGF-1 in cell culture. Its inability to bind IGFBPs means virtually all circulating IGF-1 DES is biologically active.
The short half-life limits systemic exposure but the extreme potency raises concerns about local tissue overgrowth and the same cancer-promoting risks as other IGF-1 variants.
📚 Key Reference: PMID: 2524002 (des(1-3) IGF-1 characterization)
⚠️ SIGNIFICANT RISKS. Extreme potency with short half-life. Hypoglycemia risk. Cancer promotion risk (mitogenic). Not for clinical or unsupervised use.
NOT FDA-approved. Research chemical only. High-risk compound.